Assess cancer risk and identify opportunities for increased surveillance
Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer in the world. While HCC can be effectively treated in its early stages, most patients are not diagnosed until they are symptomatic and at higher grades and stages, when the disease is less responsive to therapies. Laboratory testing and imaging can identify at-risk patients needing increased surveillance to help aid in early diagnosis.
Which test should I order?
Identify cases that would be missed by AFP alone
In a study of 74 patients14, the use of a
three-biomarker panel test detected 67 HCC cases (91%). The use of AFP alone would have detected only 45 HCC cases (60%), or 22 fewer cases than using a panel.
Learn more about how to order these evaluations at your institution.